Back to today’s briefing

Story perspectives

Novo Nordisk Slashes Semaglutide Prices; Eli Lilly Under Fire

3/28/2025

50 8

Summary

Story summary

Novo Nordisk is making waves with its new discount program for semaglutide (Wegovy), now available for $499 a month for cash-paying patients. This move seeks to enhance access to FDA-approved obesity treatments while prioritizing safety. Meanwhile, Eli Lilly's Zepbound program faces scrutiny for its higher prices and fewer choices, leaving patients worried about unapproved alternatives.

1 of 1

Story summary

Novo Nordisk is making waves with its new discount program for semaglutide (Wegovy), now available for $499 a month for cash-paying patients. This move seeks to enhance access to FDA-approved obesity treatments while prioritizing safety. Meanwhile, Eli Lilly's Zepbound program faces scrutiny for its higher prices and fewer choices, leaving patients worried about unapproved alternatives.